These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32236596)

  • 1. Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review).
    Allegra A; Innao V; Allegra AG; Pulvirenti N; Pugliese M; Musolino C
    Oncol Rep; 2020 Jun; 43(6):1729-1736. PubMed ID: 32236596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
    Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
    Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors.
    Gu Y; Wang X; Wang Y; Wang Y; Li J; Yu FX
    Cell Signal; 2020 Nov; 75():109775. PubMed ID: 32916277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC).
    Parvathaneni V; Goyal M; Kulkarni NS; Shukla SK; Gupta V
    Pharm Res; 2020 Jun; 37(7):123. PubMed ID: 32514688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
    Besse L; Kraus M; Besse A; Driessen C; Tarantino I
    Sci Rep; 2023 Mar; 13(1):4411. PubMed ID: 36932175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
    Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ
    Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6.
    Guan M; Fousek K; Jiang C; Guo S; Synold T; Xi B; Shih CC; Chow WA
    Clin Cancer Res; 2011 Apr; 17(7):1796-806. PubMed ID: 21355074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
    Kawabata S; Gills JJ; Mercado-Matos JR; Lopiccolo J; Wilson W; Hollander MC; Dennis PA
    Cell Death Dis; 2012 Jul; 3(7):e353. PubMed ID: 22825471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
    Gills JJ; Lopiccolo J; Tsurutani J; Shoemaker RH; Best CJ; Abu-Asab MS; Borojerdi J; Warfel NA; Gardner ER; Danish M; Hollander MC; Kawabata S; Tsokos M; Figg WD; Steeg PS; Dennis PA
    Clin Cancer Res; 2007 Sep; 13(17):5183-94. PubMed ID: 17785575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.
    Besse L; Besse A; Stolze SC; Sobh A; Zaal EA; van der Ham AJ; Ruiz M; Phuyal S; Büchler L; Sathianathan M; Florea BI; Borén J; Ståhlman M; Huber J; Bolomsky A; Ludwig H; Hannich JT; Loguinov A; Everts B; Berkers CR; Pilon M; Farhan H; Vulpe CD; Overkleeft HS; Driessen C
    Cancer Res; 2021 Sep; 81(17):4581-4593. PubMed ID: 34158378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
    Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
    J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
    Riddler SA; Havlir D; Squires KE; Kerr B; Lewis RH; Yeh K; Wynne LH; Zhong L; Peng Y; Deutsch P; Saah A
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3877-82. PubMed ID: 12435691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
    Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
    BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells.
    Jensen K; Bikas A; Patel A; Kushchayeva Y; Costello J; McDaniel D; Burman K; Vasko V
    Endocr Relat Cancer; 2017 Mar; 24(3):147-156. PubMed ID: 28137980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
    Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
    Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
    Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
    Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
    Dronda F; Casado JL; Moreno S; Hertogs K; García-Arata I; Antela A; Pérez-Elías MJ; Ruiz L; Larder B;
    AIDS Res Hum Retroviruses; 2001 Feb; 17(3):211-5. PubMed ID: 11177403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
    Arodola OA; Soliman ME
    Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort.
    Tsuchiya K; Matsuoka-Aizawa S; Yasuoka A; Kikuchi Y; Tachikawa N; Genka I; Teruya K; Kimura S; Oka S
    J Clin Virol; 2003 Aug; 27(3):252-62. PubMed ID: 12878089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells.
    Brüning A; Friese K; Burges A; Mylonas I
    Breast Cancer Res; 2010; 12(4):R45. PubMed ID: 20594311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.